A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Trump says he hopes Ruth Bader Ginsburg 'does really well' after tumor treatmenton August 24, 2019 at 9:40 am
WASHINGTON – President Donald Trump had encouraging words for Supreme Court Justice Ruth Bader Ginsburg as she recovers from treatment for a malignant tumor ... Ginsburg, 86, has battled back from ...
- David Axelrod after Ginsburg cancer treatment: Supreme Court vacancy could 'tear this country apart'on August 24, 2019 at 8:57 am
CNN political commentator and Democratic strategist David Axelrod David Axelrod Mark Halperin inks book deal 2020 Democrats fight to claim Obama's mantle on health care The Hill's Morning Report ...
- Ruth Bader Ginsburg Completed Cancer Treatment In Auguston August 24, 2019 at 8:44 am
Justice Ruth Bader Ginsburg has successfully completed another round of cancer treatment, her second in the past year, and given a clean bill of health, according to a statement released on Friday by ...
- Supreme Court Justice Ruth Bader Ginsburg undergoes cancer treatment for pancreatic tumoron August 23, 2019 at 5:40 pm
Supreme Court Justice Ruth Bader Ginsburg has completed a three-week course of radiation therapy for cancer, the top court said in a statement Friday. The treatment, for a tumor on her pancreas, began ...
- Ruth Bader Ginsberg Just Completed Another Cancer Treatment, and She's Good to Go.on August 23, 2019 at 2:34 pm
Supreme Court Justice Ruth Bader Ginsburg just completed three weeks of radiation therapy at Memorial Sloan Kettering Cancer Center in New York after doctors found a cancerous tumor on her pancreas, ...
- Ruth Bader Ginsburg Trends as Supreme Court Justice's Pancreatic Cancer Treatment is Announcedon August 23, 2019 at 1:59 pm
Supreme Court Justice Ruth Bader Ginsburg was at the forefront of conversation on social media on Friday–though the reason had nothing to do with politics. Users took to Twitter to react to the news ...
- Ruth Bader Ginsburg receives treatment for pancreatic canceron August 23, 2019 at 12:55 pm
Aug. 23 (UPI) --Doctors treated Supreme Court Justice Ruth Bader Ginsburg for pancreatic cancer this month, the high court announced Friday. She underwent a three-week course of radiation therapy at ...
- US Supreme Court Justice Ginsburg has more cancer treatmenton August 23, 2019 at 12:19 pm
US Supreme Court Justice Ruth Bader Ginsburg, whose repeated health battles have sparked speculation about her retirement, has undergone another round of cancer treatment, the court announced Friday.
- Supreme Court Justice Ruth Bader Ginsburg undergoes more cancer treatmenton August 23, 2019 at 11:33 am
Supreme Court Justice Ruth Bader Ginsburg has completed a three-week course of radiation therapy for cancer, the top court said in a statement Friday. The treatment began Aug. 5. Ginsburg has had ...
via Bing News